It’s been a little more than a year since the multidistrict litigation (MDL) was created surrounding complaints about C.R. Bard‘s IVC filters, and already more than 1,000 actions have been filed. The litigation has been consolidated in Arizona federal court before U.S. District Judge David G. Campbell. The Meridian model IVC filter is no longer manufactured or sold in the U.S., but lawsuits continue to pile up against the device manufacturer for IVC filters alleging the same issues.
The suits against Bard claim that the company knew, or should have known, about the devices’ alleged defects, including the tendency to fracture, migrate, tilt, perforate the vena cava wall, penetrate organs, and increase the risk for venous thrombosis. The suits also point out the lack of proper testing including clinical trials to make sure the device would function correctly.
An inferior vena cava (IVC) filter is a cage-like device that is implanted into the largest vein in the body. The purpose is to catch blood clots before they enter the heart and/or lungs, resulting in pulmonary embolism. But studies have shown that the risk may outweigh the benefit.
In 2012, a study was conducted involving 363 patients. The study estimated that 40 percent of implanted Meridian IVC filters would fracture within 5.5 years. The Meridian is similar to the Recovery model, a filter that has been linked to at least 27 deaths and hundreds of non-fatal injuries.
The Meridian is also similar to another IVC filter called the G2, which Bard had introduced as a replacement to the Recovery. However, a study conducted in June of 2014 involving 829 patients had researchers estimating that 38 percent would fracture within 5 years.
Source: Mass Tort Nexus